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1. Introduction 
Controlled ovarian hyper-stimulation (COH) is one of the most important stages in ART 
treatments. The main goal of COH is to achieve efficient follicle numbers without 
compromising oocyte quality.  
During the natural ovarian cycle, different pituitary hormones are responsible for follicle 
recruitment and growth. In the early follicular phase, follicle stimulating hormone (FSH) is 
responsible for early follicular growth and development. However, in the middle or late 
phase, reduction in FSH levels will occur and LH gains the more important role. The more 
COH protocol can mimic the natural hormonal situations, the more efficacious it will be. 
In most infertile women, the administration of exogenous FSH2 alone is usually sufficient for 
ovarian stimulation. In these patients, dominant follicles have LH receptors in addition to 
FSH ones and therefore can respond to endogenous LH. However, subgroups of cases either 
do not respond or over-respond to FSH. These patients may benefit from LH3 activity 
supplementation during their mid or late follicular phase. 
Different studies have found that LH activity supplementation may lead to improved 
outcome in patients over the age of 35, patients with initial abnormal response to 
recombinant human FSH (r-hFSH), and those at risk for poor ovarian response (Alviggi et 
al., 2006). In patients beyond 35 years, the addition of LH in form of human menopausal 
gonadotropin (hMG) to r-FSH regimen may only improve the ovarian response but does not 
improve overall pregnancy rates (Sohrabvand et al., 2010). 
On the other hand, LH components induce the local production of various molecules such 
as inhibin B and IGF-14 from granulose cells and these factors in turn promote the growth of 
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granulose cells and regulate oocyte maturation (Alviggi et al., 2006). LH is also secreted in 
the theca compartment and induces androgen production. Then these theca-driving 
androgens are converted into estradiol by aromatize enzymes (Hillier et al., 1994). These 
mechanisms may have an important role in the improvement of oocyte quality and LH or 
hCG supplementation could be a successful method for achieving the physiologic 
conditions for follicle growth.  
Different sources of LH activity including hMG, recombinant LH and low-dose hCG are 
accessible. HCG is a normal natural analogue of LH. It selectively binds to LH receptors and 
exerts the same actions as LH (Ross 1977). It has a longer half-life than LH (Nargand et al., 
2006). HCG is able to occupy LH receptors for more than 24 hours and allow stable 
stimulation of the LH receptors (Damewood et al., 1989). HCG is at least six times more 
potent than LH (Stokman et al., 1993; The European LH Study group, 2001). In other words, 
200 IU hCG is equal to 1200 IU LH. It is also less expensive than recombinant FSH or hMG 
(Fillicori et al., 2002; Filicori et al., 2005a).  
A novel gonadotropin protocol for ovarian stimulation adds low-dose hCG (50- 200 IU) in 
the late follicular phase (Filicori et al., 2002a; Filicori et al., 2002b; Filicori et al., 2005a; Lee et 
al., 2005; Sullivan et al., 1999). This component can be used alone to complete controlled 
ovarian stimulation (Filicori et al., 2005a). Usage of it in the late stage of ovarian stimulation 
(after the follicles reach≥ 12 mm) reduces gonadotropin consumption while the fertilization 
outcome is comparable (Filicori et al., 2005; Ashrafi et al., 2011). Furthermore this regimen 
reduces the number of small pre-ovulatory follicles which could reduce the risk of OHSS5 
(Fillicori et al., 2005). Adequate ovarian hormonal levels (Fillicori et al., 2005a; Branigan et 
al., 2005), oocyte maturation (Branigan et al., 2005), avoidance of a premature LH surge 
(Fillicori et al., 2005a; Branigan et al., 2005), and increased pregnancy rate (Fillicori et al., 
1999; Filicori et al., 2001) are the other benefits of this regimen. This protocol also reduces the 
stimulation duration and the dose of exogenous FSH administration (Filicori et al., 2005a); 
therefore it can minimize the patient costs. HCG might also affect endometrial function, 
stimulate endometrial growth and maturation and enhance the endometrial angiogenesis. 
These effects could extend the angiogenesis. These results could lengthen the implantation 
window (Fillicori et al., 2005a). Tesarik et al. (2003) showed that the administration of hCG 
to oocyte recipients increased the endometrial thickness on the day of embryo transfer and 
improved the implantation rate. Adding the low-dose hCG in ovarian stimulation regimens 
in PCOS patients has been associated with fewer immature oocytes (Ashrafi et al., 2011). 
Compounds containing LH activity have different risks and benefits. It is believed that LH 
has a central role in mono-follicular selection and dominance in the physiological ovulatory 
cycle (Fillicori et al., 2005a; Filicori et al., 2002c). Mono-folliculogenesis is ideal for 
intrauterine insemination (IUI), but not for IVF/ICSI treatments. In addition, LH may exert 
a deleterious effect on controlled ovarian stimulation. Unnecessary elevated levels of LH 
during the pre-ovulatory period may also negatively influence post-ovulatory events such 
as conception and implantation (Chappel & Howles, 1991). In addition, because hCG is at 
least six times more potent than LH, there is a concern that this might result in premature 
luteinization of the follicle. 
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2. Indications of LH or hCG in ovarian stimulation cycles 
As mentioned before, the use of low-dose hCG leads to suitable follicle growth and 
prevention of OHSS by small follicle atresia. Therefore, the application of LH or low-dose 
hCG in the late follicular phase could be divided to two parts. 
2.1 LH supplementation could be used for accelerating leading follicle development 
2.1.1 In patients over 35 years of age 
Women, of advanced reproductive age, have low follicular recruitment. These patients also 
have a low number of functional LH receptors and may have low biological activity of 
endogenous LH (Mitchell et al., 1995; Vihko et al., 1996). In women aged over 35 undergoing 
intra cytoplasmic sperm injection (ICSI), LH administration led to improved outcomes 
(Humaidan et al., 2004; Marrs et al., 2004). 
Ovarian paracrine activity also decreases with age (Hurwitz and Santoro, 2004). These 
paracrine variables including growth factors and cytokines may cause adequate follicular 
growth and steroidogenesis even when LH concentrations are very low (Alviggi et al., 2006). 
2.1.2 In poor ovarian responders with GnRH antagonist protocols 
In patients treated with GnRH6 antagonists, a dramatic decline in serum concentrations of 
both LH and estradiol usually occurs after administration of the drug. Therefore follicles are 
deprived of their LH substances (Alviggi et al., 2006). A stimulation regimen consisting of 
GnRH-antagonist and exogenous LH in normal responders increases estradiol production 
but has no significant effect on improvement of IVF outcomes (Cedrin-Durnerin et al., 2004; 
Griesinger et al., 2005). However, this regimen is useful for women at risk for poor ovarian 
response (patients with less than four follicles in prior cycles and/or with basal FSH 
concentrations of more than 10 IU/L) (De placido et al., 2006). 
2.2 LH supplementation could be used for patients with a tendency to over-respond 
(hyper stimulate) with standard FSH stimulation 
Some patients over-respond to FSH administration and lowering of FSH can also lead to 
follicular growth disruption. In these patients low-dose hCG substitution could be a useful 
method.  
2.2.1 In patients with polycystic ovarian syndrome 
Women with polycystic ovarian syndrome (PCOS) are the other group that may benefit 
from substituting LH for FSH in the late follicular phase. They often have multi-follicular 
development during ovarian stimulation and are at risk for ovarian hyper-stimulation 
syndrome (OHSS) or multiple pregnancy. LH activity supplementation would permit the 
more mature follicles to continue to develop while the less mature follicles would undergo 
atresia due to insufficient FSH stimulation (Zelenik & Hillier, 1984; Fillicori et al., 2002). This 
is because the more mature follicles have acquired the adequate amount of LH receptors 
during the intermediate follicular phase (Fillicori et al., 2003 a,b). 
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In our research, we assessed the effect of two low-dose hCG regimens on folliculogenesis and 
cycle outcome in PCOS patients and these regimens were compared with r-FSH alone. 
Stimulation protocol for all the patients was according to the standard long protocol (Madani 
et al., 2009). Gonadotropin stimulation commenced 14 days following subcutaneous GnRH 
agonist injection with recombinant FSH (Gonal F, Serono, Switzerland), 150 IU daily. In group 
B, ovarian priming with r-FSH7 was reduced to 75 IU once the lead follicle reached 14 mm in 
mean diameter and low-dose hCG (100 IU/day) was administered and continued until at least 
two to three follicles with a mean diameter of ≥17 mm were achieved. In group C, ovarian 
stimulation with r-FSH was discontinued and low- dose hCG (200 IU/day) was administered 
when the lead follicle reached 14 mm in mean diameter and continued until at least 2–3 
follicles with a mean diameter of 17 mm were achieved. 
We found that the substitution of hCG for r-FSH during controlled ovarian stimulation in 
infertile women with PCOS reduced the rates of immature oocytes and OHSS while yielding 
comparable fertility outcomes, since follicles in women with PCOS, as with follicles in 
eumenorrheic women, become LH responsive as they mature. We also observed lower 
gonadotropin consumption following the addition low-dose hCG in the late follicular phase 
in PCOS patients (Ashrafi et al., 2011). 
3. Low-dose hCG starting time 
Low-dose hCG supplementation could be used in most ART protocols. However, the start 
time of hCG administration and discontinuation or decreasing of FSH are two important 
issues. In most trials, the administration of low-dose hCG was started during the middle or 
late follicular phase or when the follicle reached a size of more than 10 mm. In these 
conditions receptors for LH or hCG on the granulose cells are capable of supporting 
continued growth of the follicles in the absence of FSH administration (Filicori et al., 2005b). 
Low-dose hCG has also been started at the time of beginning stimulation with r-FSH (Van 
horn et al. 2007).  
4. Low-dose hCG administration in assisted reproductive technologies 
The addition of low-dose hCG has been used in different protocols: 
4.1 In patients undergoing ovarian stimulation for timed intercourse and intra uterine 
insemination (IUI) 
The main aim of ovarian stimulation in IUI cycles is mono follicular development. Ovarian 
stimulation regimens containing the FSH alone or combining the FSH and LH usually cause 
multi-follicular development. The low-dose hCG supplementation after the FSH priming 
may reduce the number of developing follicles (Fillicori et al., 2002a; 2002c; 2003a). 
This regimen is also useful for patients who have previously failed to ovulate with 
clomiphen citrate. Branigan et al. (2006) in their RCT evaluated the effect of the low dose- 
hCG in previously anovulatory patients on clomiphen citrate (CC) alone. These patients 
underwent ovarian stimulation with CC at the 100 mg dose for timed intercourse in their 
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previous cycles and failed to ovulate on this regimen. They found that the use of low dose- 
hCG (200IU) after CC in the late follicular phase resulted in good ovulation and pregnancy 
rates in these patients. 



















Fig. 1. Clomiphen Citrate + Low-dose hCG 
4.2 Low dose hCG administration in conjunction with GnRH antagonists 
The use of GnRH antagonist instead of GnRH agonist in IVF cycles has increased in recent 
years. Different strategies could be used for GnRh antagonist administration. A single depot 
maybe used on cycle stimulation day eight or nine which lasts four days and is sufficient to 
prevent the LH surge in 80%of women (Olivennes et al., 1998). Alternatively, multiple small 
doses may be used daily from cycle day six as a fixed order, or when the leading follicle has 
reached a 14 mm diameter in a more flexible manner, until the hCG trigger. 
This protocol has some benefits. For example, it can lead to immediate pituitary suppression 
(Tarlatzis et al., 2006). The decreasing of OHSS, lowering the gonadotropin consumption, and 
avoidance of the gonadotropin flare are the other benefits of this protocol (Tarlatzis et al., 2006; 
Griesinger et al., 2010). However, the LH level in the GnRH antagonist protocol decreases 
(Duijkers et al., 1998; Griesinger et al., 2010) and this may negatively affect implantation or 
pregnancy rate (Esposito et al., 2001). LH secretion is necessary for appropriate follicular and 
endometrial development (Shoham et al., 2008; Kaufmann et al., 2007).  
Adding the low-dose hCG to the GnRH antagonist protocol may compensate for its 
shortcomings. It can be added to all types of GnRH antagonist protocols which have been 
mentioned before. It may improve the implantation and live birth rates in patients with low 
LH levels (Propst et al., 2011). Low-dose hCG supplementation results in higher estradiol 
secretion of granulose cells and cumulous cell expansion that causes better oocyte maturation 
rates and endometrial preparation (Cedrin-Durnerin et al., 2004; Ben-Ami et al., 2009). The 
effect of hCG on endometrium regulation and implantation has been suggested in previous 
studies (Filicori et al., 2005; Cameo et al., 2006; d’Hauterive et al., 2007). LH administration can 
increase the LH/hCG receptors during the pre-implantation window and also prevents 
apoptosis of the endometrial stromal cells (Lovely et al., 2005; Jasinska et al., 2006).  
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Serafini et al. (2006) showed that using a low-dose hCG protocol along with a GnRH 
antagonist treatment in normal ovarian responders avoids premature ovulation, and OHSS. 
It also decreases the total dose of recombinant FSH. This protocol permitted follicles and 
oocytes to develop fully and aided normal fertilization along with the generation of top-
quality embryos and establishment of clinical pregnancies. 
Van Horne et al., (2007) also found a reduction in r-FSH requirements and an average cost 
saving of $600 per cycle in patients who used low-dose hCG supplementation in the GnRH 
antagonist cycles. These patients had similar implantation and pregnancy rates compared 
with GnRH antagonist cycles that used r-FSH alone. 










































Fig. 2. GnRH antagonist (Single Dose) + Low dose hCG 


























Fig. 3. GnRH antagonist (Multiple Dose) + Low dose hCG 
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4.3 Low-dose hCG administration in women undergoing IVF cycles down-regulated 
with GnRH agonists 
There are two protocols for the usage of GnRH agonists in ART cycles. 
1. Long protocol 
For this protocol, all patients usually receive Buserelin 500 µgr (0.5 mg) via subcutaneous 
injection starting on day 21 of their menstrual cycles. Down-regulation is confirmed by a 
linear endometrium in ultrasonography (endometrium below 3 mm) and suppressed 
ovaries by serum estradiol concentration< 60 pg/ml. Gonadotropin stimulation commence 
14 days following subcutaneous GnRH agonist injection with recombinant FSH, 150 IU 
daily. The dose of GnRH agonist will be decreased at this moment (to 200 µgr). The dose 
and duration of FSH treatment are adjusted by monitoring follicular development with 
ultrasound and estradiol levels. FSH administration is discontinued and low-dose hCG is 
added when the lead follicle reached to more than 12 mm. The goal of ovarian stimulation is 
to achieve at least two ovarian follicles with a mean diameter of ≥17 mm on the day of hCG 
administration. Then, 10,000 IU of hCG is administered and oocyte retrieval is performed 
34–36 hours later. 
























GnRH 0.2 mg SQ

















Fig. 4. GnRH Agonist Long Protocol+ 200 IU Low Dose hCG 
2.  Short protocol 
The short or flare protocol employs the agonist-induced flare-up of endogenous FSH to 
stimulate the ovary in addition to exogenous FSH administration. The agonist is started on 
day two of the cycle with gonadotrophins on day three. Follicular growth takes 10–12 days 
which is adequate to down-regulate the pituitary gland and prevent a premature LH surge 
(Daya, 2000). The administration of recombinant FSH, 150 IU daily will be discontinued 
when the lead follicle reached to more than 12 mm. In this condition low dose hCG is 
added. The goal of ovarian stimulation is to achieve an average of two ovarian follicles with 
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a mean diameter of ≥17 mm on the day of hCG administration. Then, 10,000 IU of hCG is 
administered and oocyte retrieval is performed 34–36 h later. 


























Fig. 5. GnRH Agonist Short Protocol+ 200 IU Low Dose hCG 
5. Conclusion 
Use of low-dose hCG in the mid to late follicular phase of COH provides these results: 
1. This protocol provides adequate ovarian estradiol secretion, oocyte maturation, and 
acceptable fertilization rates. 
2. This protocol provides significant reduction of FSH dosage and reduced cost of treatment. 
3. This protocol has no adverse effects on the number of oocyte retrieved and pregnancy 
rate but can prevent the occurrence of OHSS with a reduced number of follicles and 
cancelled cycles. 
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